LONDON Aug 20 Celgene's drug Revlimid
should be an option on Britain's state health service for
patients with serious bone marrow disorders and a specific
chromosomal abnormality, the country's cost agency said on
The final draft guidance from the National Institute for
Health and Care Excellence (NICE) represents a change of tack
after the medicine was rejected last year for treating
myelodysplastic syndromes, which can lead to life-threatening
diseases including leukaemia.
The latest decision follows the submission of revised
analyses from Celgene and further information on the company's
proposal to limit the cost of the drug. Celgene has agreed to
provide Revlimid free of charge for anyone who needs more than
26 monthly cycles of treatment.
The draft guidance is now open for consultation before NICE
issues final guidance.
(Reporting by Ben Hirschler; Editing by Pravin Char)